Spero Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

Spero Therapeutics is currently at a crossroads, where the resolution of a long-standing SEC investigation and the streamlining of its portfolio have cleared the path for a definitive catalyst. The company has effectively de-risked its immediate survival through a robust cash pile of $56.1 million, shifting the investor focus entirely toward the June 2026 FDA decision. The fundamental trade-off for investors is the ability to withstand the binary nature of the PDUFA date against the potential for massive asymmetric upside via GSK milestones. Ultimately, the filing reveals a company that has outsourced its primary risk and reward to a partner. While the financial metrics show a disciplined reduction in spending, the lack of a diversified pipeline means that any negative FDA outcome would be catastrophic. The next few months will determine if Spero's pivot to a lean, milestone-driven model was a masterstroke of capital preservation or a desperate move to extend a dwindling runway.